

<b>SOP: Training and Coverage Requirements for Investigators Conducting Clinical Trials and Clinical Investigations</b>				
NUMBER	DATE	AUTHOR	APPROVED BY	PAGE
HRP-093	08/23/2017	C. Gates	C. Kiel	1 of 1

NUMBER	DATE	AUTHOR	APPROVED BY	PAGE
HRP-093	08/23/2017	C. Gates	C. Kiel	1 of 1

**1 PURPOSE**

1.1 This policy establishes the requirements for investigators who conduct [clinical trials](#) and [clinical investigations](#).

**2 REVISIONS FROM PREVIOUS VERSION**

2.1 None

**3 POLICY**

3.1 Principal Investigators must ensure that all research personnel have completed the following training prior to conducting any research activities:

3.1.1 For research involving only minimal risk:

3.1.1.1 [NIH Program Protecting Human Research Participants](#);

3.1.1.2 [CITI online Basic Human Research Protections Training for Biomedical Researcher](#); or

3.1.1.3 [CITI online Basic Human Research Protections Social Behavioral Researchers and staff](#).

3.1.2 For social behavioral clinical trials:

3.1.2.1 [GCP – Social and Behavioral Research Best Practices for Clinical Research](#).

3.1.3 For clinical investigations subject to FDA jurisdiction:

3.1.3.1 [GCP for Clinical Trials with Investigational Drugs and Biologics \(ICH Focus\)](#);

or

3.1.3.2 [GCP for Clinical Trials with Investigational Medical Devices](#).

3.2 For biomedical trials involving greater than minimal risk, Principal Investigators must ensure that a responsible person is available to provide medical care to research participants whenever the principal investigator is unavailable to provide said care. This responsible person must:

3.2.1 Be included on the Research Personnel List on the Electronic Initial Review Application or on [FORM HRP 215 Research Personnel List Template](#) if there is no electronic application.

3.2.2 Have sufficient medical training to oversee the medical care of participants; and

3.2.3 Have sufficient training on the protocol requirements to avoid deviations from the protocol requirements unless the deviation is necessary to prevent imminent harm to participants.

3.3 When a Principal Investigator leaves his/her position at UC Davis, s/he must perform one of the following actions with respect to all clinical trials and clinical investigations for which s/he is the Principal Investigator:

3.3.1 Close the study;

3.3.2 Transfer close the study to a qualified Principal Investigator at UC Davis as outlined in the UC Davis Investigator Manual; or

3.3.3 Work with IRB Administration to develop an alternative plan for supervision of the research.

**4 MATERIALS**

4.1 None

**5 REFERENCES**

5.1 None